PDK4 and Other metabolic disease: As an increase in the PDHC activity by a PDK4 inhibitor promotes glucose oxidation and lowers the blood glucose concentration, small molecule inhibitors for PDKs are promising therapeutic agents for patients with metabolic diseases.